Literature DB >> 30190980

The evolving field of intrahepatic cholangiocarcinoma.

Miral Sadaria Grandhi1, Andrew J Page1, Timothy M Pawlik1.   

Abstract

Entities:  

Keywords:  biliary tract cancer; incidence; intrahepatic cholangiocarcinoma; staging

Year:  2015        PMID： 30190980      PMCID： PMC6095417          DOI： 10.2217/hep.14.30

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN： 2045-0923


× No keyword cloud information.
  29 in total

1.  The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.

Authors:  A H Patel; D M Harnois; G G Klee; N F LaRusso; G J Gores
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

Review 2.  Intrahepatic cholangiocarcinoma: management options and emerging therapies.

Authors:  Rebecca M Dodson; Matthew J Weiss; David Cosgrove; Joseph M Herman; Ihab Kamel; Robert Anders; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-07-24       Impact factor: 6.113

3.  Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.

Authors:  Daniela Sia; Yujin Hoshida; Augusto Villanueva; Sasan Roayaie; Joana Ferrer; Barbara Tabak; Judit Peix; Manel Sole; Victoria Tovar; Clara Alsinet; Helena Cornella; Brandy Klotzle; Jian-Bing Fan; Christian Cotsoglou; Swan N Thung; Josep Fuster; Samuel Waxman; Juan Carlos Garcia-Valdecasas; Jordi Bruix; Myron E Schwartz; Rameen Beroukhim; Vincenzo Mazzaferro; Josep M Llovet
Journal:  Gastroenterology       Date:  2013-01-04       Impact factor: 22.682

4.  Biliary tract cancers in Olmsted County, Minnesota, 1976-2008.

Authors:  Ju Dong Yang; Bohyun Kim; Schuyler O Sanderson; Jennifer St Sauver; Barbara P Yawn; Joseph J Larson; Terry M Therneau; Lewis R Roberts; Gregory J Gores; W Ray Kim
Journal:  Am J Gastroenterol       Date:  2012-07-03       Impact factor: 10.864

5.  Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.

Authors:  Takahiro Uenishi; Osamu Yamazaki; Hiromu Tanaka; Shigekazu Takemura; Takatsugu Yamamoto; Shogo Tanaka; Shuhei Nishiguchi; Shoji Kubo
Journal:  Ann Surg Oncol       Date:  2007-10-23       Impact factor: 5.344

6.  Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma.

Authors:  Christopher D Anderson; Michael H Rice; C Wright Pinson; William C Chapman; Ravi S Chari; Dominique Delbeke
Journal:  J Gastrointest Surg       Date:  2004-01       Impact factor: 3.452

7.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

8.  Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis.

Authors:  Omar Hyder; J Wallis Marsh; Riad Salem; Elena N Petre; Sanjeeva Kalva; Eleni Liapi; David Cosgrove; Donielle Neal; Ihab Kamel; Andrew X Zhu; Constantinos T Sofocleous; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2013-07-12       Impact factor: 5.344

9.  Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?

Authors:  Shahid A Khan; Shireen Emadossadaty; Nimzing G Ladep; Howard C Thomas; Paul Elliott; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

10.  Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.

Authors:  J W Valle; H Wasan; P Johnson; E Jones; L Dixon; R Swindell; S Baka; A Maraveyas; P Corrie; S Falk; S Gollins; F Lofts; L Evans; T Meyer; A Anthoney; T Iveson; M Highley; R Osborne; J Bridgewater
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.